Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




PSA Can Help Identify Cancer Following Surgery for Benign Prostatic Hyperplasia

By LabMedica International staff writers
Posted on 09 Jul 2009
Men undergoing surgical interventions for benign prostatic hyperplasia (BPH) are still at risk for subsequent development of prostate cancer due to residual tissue, claims a new study. More...


Researchers at Northwestern University (Chicago, IL, USA) conducted a retrospective review of 525 patients who had undergone one of three procedures for BPH: transurethral resection of the prostate (TURP; 343 patients), holmium laser resection of the prostate (HoLRP; 54 patients), or open prostatectomy (OP; 68 patients), between 1992 and 2007. The prostate-specific antigen (PSA) and PSA velocity values were collected at regular intervals both pre- and postoperatively for all patients, since the researchers hypothesized that the PSA level might be influenced by the efficacies of different BPH procedures. Only patients with histologic BPH and those with incidental prostate cancer who underwent a watchful waiting strategy were included.

The researchers found that the average preoperative PSA values were significantly different between the TURP, HoLRP, and OP groups. Only one patient had incidental prostate cancer in the HoLRP group. No differences were present between the preoperative PSA values for patients with histologic BPH and those with incidental prostate cancer undergoing a watchful waiting strategy. However, the postoperative PSA values were increased in the patients with prostate cancer; similarly, patients with incidental prostate cancer had a significantly elevated postoperative mean PSA velocity compared with patients without prostate cancer. The researchers therefore concluded that postoperative PSA and PSA velocity measurements could be used to distinguish patients with prostate cancer from those with histologic BPH only. The study was published ahead of print on May 8, 2009, in the online edition of Urology.

Prostatic adenoma inevitably remains after BPH surgery, and studies have determined that the level of PSA decreases by approximately 0.1-0.3 ng/ml for every gram of prostate tissue removed. Therefore, PSA levels should indicate residual hyperplastic tissue, as well as resulting cancer risk.

Related Links:

Northwestern University



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.